semaglutide loss of exclusivity Off-patent in 2026: the next revolution in anti-obesity medications Skinny jabs': weight-loss drugs set

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases

Visceral fat (the fat surrounding abdominal organs) is the depot most strongly linked to metabolic disease, so a reduction of this size is clinically meaningful

Biannual liver ultrasonography and serum -fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV)

Personalized Food Idea Assistant : Get personalized meal ideas when food noise disappears

Sustain results after GLP-1s with Virtas nutrition therapy that addresses the root cause of obesity and unhealthy weight A proven approach for deprescribing GLP-1s when clinically appropriate Our first of its kind research study shows sustained weight loss after deprescribing GLP-1s among a real world population

While this warning has been added to the Wegovy warning label in the UK, its still not included on the U.S